Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma USA, is partnering with Treehill Partners, a US-based financial and deal-making advisory firm specializing in the healthcare sector. The collaboration aims to establish a jointly operated investment vehicle targeting individual clinical-stage assets.
Targeting High-Potential Clinical-Stage Assets
The investment focus will be on high-quality, mid- to late-stage assets under development for the US market, as well as high-quality candidates seeking market entry outside the US. The partnership aims to address the industry’s recent stagnation due to restricted capital availability for biotech product development, providing both funding and expertise to accelerate the development of promising molecules for the US market. Initial investments are anticipated in 2024. While Fosun USA serves as a bridge to the Chinese market, the primary focus remains on US market entry.
Fosun Pharma USA’s Strategic Role and Partnerships
Established in 2017, Fosun Pharma USA was created to forge strategic partnerships and establish a commercial presence in the US on behalf of the Shanghai-based parent company. In a significant move, Fosun USA licensed rights to develop the PD-1 inhibitor serplulimab on behalf of another Fosun subsidiary, Shanghai Henlius Biotech, in January 2023. Henlius initiated a US bridging study in 2022, assessing serplulimab against Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC).- Flcube.com
